Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer

Lung Cancer

Volumn 74, Issue 2, 2011, Pages 248-252

  Sakakibara Konishi, Jun ^a   Oizumi, Satoshi ^a   Kinoshita, Ichiro ^b   Shinagawa, Naofumi ^a   Kikuchi, Junko ^a   Kato, Mototsugu ^c   Inoue, Tetsuya ^b   Katoh, Norio ^b   Onimaru, Rikiya ^b   Shirato, Hiroki ^b   Dosaka Akita, Hirotoshi ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer; Paclitaxel; Phase I study; Radiation

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; HUMAN; JAPAN; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; REAL TIME TUMOR TRACKING RADIATION THERAPY; THORAX; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 80053638392     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.02.009     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
3. Okamoto I. Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan. Int J Clin Oncol 2008, 13:112-116.
4. Machtay M., Hsu C., Komaki R., Sause W.T., Swann R.S., Langer C.J., et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005, 63:667-671.
5. Choy H. Taxanes in combined-modality therapy for solid tumors. Oncology (Williston Park) 1999, 13:23-38.
6. Choy H., Akerley W., Safran H., Clark J., Rege V., Phase I Trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 1994, 12:2682-2686.
7. Choy H., Safran H., Akerley W., Graziano S.L., Bogart J.A., Cole B.F. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 1998, 4:1931-1936.
8. Choy H., Akerley W., Safran H., Graziano S., Chung C., Williams T., et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998, 16:3316-3322.
9. Endo M., Takada Y., Obayashi K., Kotani Y., Satouchi M., Kado T., et al. Weekly paclitaxel and carboplatin with concurrent radiation therapy in locally advanced non-small cell lung cancer: phase I study. Radiat Med 2005, 23:331-335.
10. Shirato H., Shimizu S., Shimizu T., Nishioka T., Miyasaka K. Real-time tumour-tracking radiotherapy. Lancet 1999, 353:1331-1332.
11. Harada T., Shirato H., Ogura S., Oizumi S., Yamazaki K., Shimizu S., et al. Real-time tumor-tracking radiation therapy for lung carcinoma by the aid of insertion of a gold marker using bronchofiberscopy. Cancer 2002, 95:1720-1727.
12. Shirato H., Harada T., Harabayashi T., Hida K., Endo H., Kitamura K., et al. Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:240-247.
13. Shirato H., Shimizu S., Kitamura K., Onimaru R. Organ motion in image-guided radiotherapy: lessons from real-time tumor-tracking radiotherapy. Int J Clin Oncol 2007, 12:8-16.
14. Giraud P., Antoine M., Larrouy A., Milleron B., Callard P., De Rycke Y., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48:1015-1024.
15. Werner-Wasik M., Yorke E., Deasy J., Nam J., Marks L.B. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys 2010, 76:S86-93.
16. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45:323-329.
17. Tsujino K., Hirota S., Endo M., Obayashi K., Kotani Y., Satouchi M., et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2003, 55:110-115.
18. David G., Pfister D.H.J., Christopher G.A., Sausse W., Smith T.J., Bajer S., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004, 22:330-353.
19. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003, 22. abstr. 2499.
20. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
21. Bunn P.A., Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998, 4:1087-1100.
22. Segawa Y., Kiura K., Takigawa N., Kamei H., Harita S., Hiraki S., et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010, 28:3299-3306.
23. Yamamoto N., Nakagawa K., Nishimura Y., Tsujino K., Satouchi M., Kudo S., et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010, 28:3739-3745.
24. Socinski M.A., Rosenman J.G., Halle J., Schell M.J., Lin Y., Russo S., et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B non small cell lung carcinoma: a modified phase I/II trial. Cancer 2001, 92:1213-1223.
25. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.